Alternatively, if DDAH2 does not metabolise ADMA, then development of ADMA-lowering therapies should be targeted towards DDAH1, while drug development targeting DDAH2 should be redirected towards its ADMA-independent biological effects in regulation of angiogenesis, diabetes, and immune responses. This evidence concerns the gene DDAH2 and diabetes mellitus.